http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2656984-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16c3929442960d940ef1e6aa830b57c9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J53-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J63-00 |
| filingDate | 2013-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3449b6a00ece8220607c262005b3b98a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc3f42fd4802f7043a0d5073d13ce7da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19e10ddbd77d3d0328dd91821b5ab4fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_359bd3696476d5ff6c3852c020b4266b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a1f4cdd2e0457e2c57e26a8fceb3f93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9eec2eccdbe287642dc5c4def90275 |
| publicationDate | 2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2656984-T3 |
| titleOfInvention | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| abstract | A compound selected from the group consisting of: a compound of formula I ** Formula ** a compound of formula II ** Formula ** a compound of formula III ** Formula ** and a compound of formula IV ** Formula * * in which R1 is isopropenyl or isopropyl; J and E are independently -H or -CH3, and E is absent when the double bond is present; X is selected from the group C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxocycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxocycloalkenyl, C6- cycloalkenyl, C6- cycloalkenyl, C6-6 alkenyl C6 oxaccyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl, in which X is substituted with A, in which A is at least one member selected from the group of -H, -halo, -hydroxyl, -C1-6 alkyl , -C 1-6 alkoxy, -C 1-6 alkyl, -C 1-6 alkyl substituted with alkyl-Q, -CN, -CF2Q, -NR8R9, -COOR2 and -CONR2R2. X can also be selected from the group of: ** Formula ** in which Q is selected from the group of aryl, heteroaryl, substituted heteroaryl, -OR2, -COOR3, -NR2R2, - SO2R7, -CONHSO2R3, and -CONHSO2NR2R2 ; R 2 is -H, -C 1-6 alkyl, -C 1-6 alkyl substituted with C 1-6 alkyl or aryl substituted with alkyl; Y is selected from the group of -COOR2, -C (O) NR2SO2R3, -C (O) NHSO2NR2R2, -NR2SO2R2, -SO2NR2R2, - C3-6 -C10 -alkyl alkyl, -C2 -alkenyl 6-COOR2, -C1-6 alkyl-COOR2, -C1-6 alkyl substituted with alkyl, CF2-COOR2, -NHC (O) (CH2) n-COOR2, -SO2NR2C (O) R2, -tetrazol, and -CONHOH , in which n> = 1-6; W is absent, CH2 or CO; R3 is -C 1-6 alkyl or -C 1-6 alkyl substituted by alkyl; R4 is selected from the group of -H, -C1-6 alkyl, -C1-6-C alkyl (OR3) 2-C3-6 cycloalkyl, -C1-6 substituted alkyl, - C1-6 alkyl-C3-6 cycloalkyl , -C1-6-Q1 alkyl, -C1-6 alkyl-C3-6-Q1 cycloalkyl, aryl, heteroaryl, substituted heteroaryl, -COR6, -COCOR6, -SO2R7, -SO2NR2R2, ** Formula ** with the condition of that R4 or R5 cannot be COR6 or COCOR6 when W is CO; wherein Q1 is selected from the group of heteroaryl, substituted heteroaryl, halogen, -CF3, -OR2, -COOR2, - NR8R9, -CONR1QR11 and -SO2R7; R5 is selected from the group of -H, -C1-6 alkyl, -C3-6cycloalkyl, -C1-6 alkyl substituted with alkyl, -C1-6 alkyl-NR8R9, -COR10, -COR6, -COCOR6, -SO2R7 and -SO2NR2R2; with the proviso that only one of R4 or R5 can be selected from the group of -COR6, -COCOR6, -SO2R7 and - SO2NR2R2; or when W is absent or is CH2, then R4 and R5 can be taken together with adjacent N to form ** Formula ** R6 is selected from the group of -H, -C1-6 alkyl, -C1-6 alkyl substituted with alkyl, -C3-6 cycloalkyl, -C3-6 substituted cycloalkyl-Q2, -C1-6-Q2 alkyl, -C1-6 alkyl substituted with -Q2 alkyl, -C3-6-Q2 cycloalkyl, aryl-Q2, - NR13R14 , and -OR15; wherein Q2 is selected from the group of aryl, heteroaryl, substituted heteroaryl, -OR2, -COOR2, -NR8R9, SO2R7, -CONHSO2R3, and -CONHSO2Nr2R2; R7 is selected from the group of -C 1-6 alkyl, -C 1-6 substituted alkyl, -C 3-6 cycloalkyl, -CF 3, aryl, and heteroaryl; R8 and R9 are independently selected from the group of -H, -C1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, -C1-6 alkyl-Q2 alkyl, and -COOR3, and R8 and R9 can also be selected independently between the group of ** Formula ** or R8 and R9 are taken together with the adjacent N to form a cycle selected from the group of: ** Formula ** with the proviso that only one of R8 or R9 can be -COOR3 ; R10 and R11 are independently selected from the group of -H, -C1-6 alkyl, -C1-6 substituted alkyl and -C3-6 cycloalkyl, or R10 and R11 are taken together with the adjacent N to form a cycle such as * * Formula ** R12 is selected from the group of -C 1-6 alkyl, -C 1-6 alkyl-OH; -C1-6 alkyl, -C1-6 substituted alkyl, -C3-6 cycloalkyl, -COR7, -COONR22R23, -SOR7, and -SONR24R25; R13 and R14 are independently selected from the group of -H, -C1-6 alkyl, -C3-6 alkylcycloalkyl, substituted C1-6 alkyl, -C1-6 alkyl-Q3, -C1-6 alkyl-C3-6 alkyl -Q3, substituted C1-6 alkyl-Q3 and ** Formula ** or R13 and R14 are taken together with the adjacent N to form a cycle selected from the group of: ** Formula ** Q3 is selected from the heteroaryl group, substituted heteroaryl, -NR20R21, -CONR2R2, -COOR2, -OR2, and -SO2R3; R15 is selected from the group of -C 1-6 alkyl, -C3-6 cycloalkyl, -C1-6 substituted alkyl, -C1-6-Q3 alkyl, -C1-6 alkyl-C3-6-Q3 alkyl and alkyl- C1-6 substituted-Q3. R16 is selected from the group of -H, -C 1-6 alkyl, -NR2R2, and -COOR3; R17 is selected from the group of -H, -C 1-6 alkyl, -COOR3, and aryl; R18 is selected from the group of -COOR2 and alkyl-C1-6-COOR2; R19 is selected from the group of -H, -C 1-6 alkyl, -C 1-6 alkyl-Q4, -COR3, -COOR3, in which Q4 is selected from the group of -NR2R2 and -OR2; R20 and R21 are independently selected from the group of -H, -C1-6 alkyl, -C1-6 substituted alkyl, -C1-6 substituted alkyl-OR2, and -COR3, or R20 and R21 are taken together with the adjacent N to form a cycle selected from the group of ** Formula ** with the proviso that only one of R20 or R21 can be -COR3; R22 and R23 are independently selected from the group of H, -C1-6 alkyl, -C1-6 substituted alkyl and -C1-6 cycloalkyl, or R22 and R23 are taken together with the adjacent N to form a cycle selected from the group of ** Formula ** R24 and R25 are independently of the group of H, -C1-6 alkyl, -C1-6 substituted alkyl, -C1-6-Q5 alkyl, - C1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q5 is selected from the halogen group and SO2R3; or pharmaceutically acceptable salts thereof. |
| priorityDate | 2012-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 292.